Literature DB >> 25865650

Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia.

Parinda A Mehta1, Mei-Jie Zhang2, Mary Eapen3, Wensheng He3, Adriana Seber4, Brenda Gibson5, Bruce M Camitta6, Carrie L Kitko7, Christopher C Dvorak8, Eneida R Nemecek9, Haydar A Frangoul10, Hisham Abdel-Azim11, Kimberly A Kasow12, Leslie Lehmann13, Marta Gonzalez Vicent14, Miguel A Diaz Pérez14, Mouhab Ayas15, Muna Qayed16, Paul A Carpenter17, Sonata Jodele18, Troy C Lund19, Wing H Leung20, Stella M Davies18.   

Abstract

Children with hypodiploid acute lymphoblastic leukemia (ALL) have inferior outcomes despite intensive risk-adapted chemotherapy regimens. We describe 78 children with hypodiploid ALL who underwent hematopoietic stem cell transplantation between 1990 and 2010. Thirty-nine (50%) patients had ≤ 43 chromosomes, 12 (15%) had 44 chromosomes, and 27 (35%) had 45 chromosomes. Forty-three (55%) patients underwent transplantation in first remission (CR1) and 35 (45%) underwent transplantation in ≥ second remission (CR2). Twenty-nine patients (37%) received a graft from a related donor and 49 (63%) from an unrelated donor. All patients received a myeloablative conditioning regimen. The 5-year probabilities of leukemia-free survival, overall survival, relapse, and treatment-related mortality for the entire cohort were 51%, 56%, 27%, and 22%, respectively. Multivariate analysis confirmed that mortality risks were higher for patients who underwent transplantation in CR2 (hazard ratio, 2.16; P = .05), with number of chromosomes ≤ 43 (hazard ratio, 2.15; P = .05), and for those who underwent transplantation in the first decade of the study period (hazard ratio, 2.60; P = .01). Similarly, treatment failure risks were higher with number of chromosomes ≤ 43 (hazard ratio, 2.28; P = .04) and the earlier transplantation period (hazard ratio, 2.51; P = .01). Although survival is better with advances in donor selection and supportive care, disease-related risk factors significantly influence transplantation outcomes.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Hypodiploid acute lymphoblastic leukemia

Mesh:

Substances:

Year:  2015        PMID: 25865650      PMCID: PMC4465998          DOI: 10.1016/j.bbmt.2015.04.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

1.  Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.

Authors:  D Przepiorka; K W Chan; R E Champlin; S J Culbert; D Petropoulos; C Ippoliti; I Khouri; Y O Huh; H Vreisendorp; A B Deisseroth
Journal:  Bone Marrow Transplant       Date:  1995-12       Impact factor: 5.483

2.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Authors:  Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

3.  Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.

Authors:  James B Nachman; Nyla A Heerema; Harland Sather; Bruce Camitta; Erik Forestier; Christine J Harrison; Nicole Dastugue; Martin Schrappe; Ching-Hon Pui; Giuseppe Basso; Lewis B Silverman; Gritta E Janka-Schaub
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

4.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

Authors:  A Möricke; M Zimmermann; A Reiter; G Henze; A Schrauder; H Gadner; W D Ludwig; J Ritter; J Harbott; G Mann; T Klingebiel; F Zintl; C Niemeyer; B Kremens; F Niggli; D Niethammer; K Welte; M Stanulla; E Odenwald; H Riehm; M Schrappe
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

5.  Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia.

Authors:  Christine J Harrison; Anthony V Moorman; Zoë J Broadfield; Kan L Cheung; Rachel L Harris; G Reza Jalali; Hazel M Robinson; Kerry E Barber; Sue M Richards; Christopher D Mitchell; Tim O B Eden; Ian M Hann; Frank G H Hill; Sally E Kinsey; Brenda E S Gibson; John Lilleyman; Ajay Vora; Anthony H Goldstone; Ian M Franklin; Jill Durrant; Mary Martineau
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

6.  Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.

Authors:  Daniel Weisdorf; Stephen Spellman; Michael Haagenson; Mary Horowitz; Stephanie Lee; Claudio Anasetti; Michelle Setterholm; Rebecca Drexler; Martin Maiers; Roberta King; Dennis Confer; John Klein
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

7.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors:  Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

8.  Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

Authors:  Anjo J Veerman; Willem A Kamps; Henk van den Berg; Eva van den Berg; Jos P M Bökkerink; Marrie C A Bruin; Marry M van den Heuvel-Eibrink; Carin M Korbijn; Elisabeth T Korthof; Karin van der Pal; Theo Stijnen; Margreet H van Weel Sipman; J Fransje van Weerden; Elisabeth R van Wering; Anna van der Does-van den Berg
Journal:  Lancet Oncol       Date:  2009-09-09       Impact factor: 41.316

9.  Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Authors:  Ching-Hon Pui; Dario Campana; Deqing Pei; W Paul Bowman; John T Sandlund; Sue C Kaste; Raul C Ribeiro; Jeffrey E Rubnitz; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; Larry E Kun; Sima Jeha; Cheng Cheng; Scott C Howard; Vickey Simmons; Amy Bayles; Monika L Metzger; James M Boyett; Wing Leung; Rupert Handgretinger; James R Downing; William E Evans; Mary V Relling
Journal:  N Engl J Med       Date:  2009-06-25       Impact factor: 91.245

10.  Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001.

Authors:  C Mitchell; S Richards; C J Harrison; T Eden
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more
  11 in total

Review 1.  What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?

Authors:  Aimee C Talleur; Shannon L Maude
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.

Authors:  Sarah K Tasian; Stephen P Hunger
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 3.  CAR T cells vs allogeneic HSCT for poor-risk ALL.

Authors:  Caroline Diorio; Shannon L Maude
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Ernesto Diaz-Flores; Evan Q Comeaux; Kailyn L Kim; Ella Melnik; Kyle Beckman; Kara L Davis; Kevin Wu; Jon Akutagawa; Olga Bridges; Roberta Marino; Margo Wohlfeil; Benjamin S Braun; Charles G Mullighan; Mignon L Loh
Journal:  Cancer Res       Date:  2019-03-12       Impact factor: 12.701

5.  Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

Authors:  Jennifer L McNeer; Meenakshi Devidas; Yunfeng Dai; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Samir B Kahwash; Michael J Borowitz; Brent L Wood; Eric Larsen; Kelly W Maloney; Leonard Mattano; Naomi J Winick; Kirk R Schultz; Stephen P Hunger; William L Carroll; Mignon L Loh; Elizabeth A Raetz
Journal:  J Clin Oncol       Date:  2019-02-11       Impact factor: 50.717

6.  Group-Based Trajectory Modeling of Distress and Well-Being Among Caregivers of Children Undergoing Hematopoetic Stem Cell Transplant.

Authors:  Stephen A Sands; Laura Mee; Abraham Bartell; Sharon Manne; Katie A Devine; Mirko Savone; Deborah A Kashy
Journal:  J Pediatr Psychol       Date:  2017-04-01

7.  Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.

Authors:  Ching-Hon Pui; Paola Rebora; Martin Schrappe; Andishe Attarbaschi; Andre Baruchel; Giuseppe Basso; Hélène Cavé; Sarah Elitzur; Katsuyoshi Koh; Hsi-Che Liu; Kajsa Paulsson; Rob Pieters; Lewis B Silverman; Jan Stary; Ajay Vora; Allen Yeoh; Christine J Harrison; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2019-01-18       Impact factor: 50.717

Review 8.  Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia.

Authors:  Haneen Shalabi; Anne Angiolillo; Terry J Fry
Journal:  Front Pediatr       Date:  2015-10-01       Impact factor: 3.418

9.  Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis.

Authors:  M S Zinter; B D Barrows; P C Ursell; K Kowalek; K Kalantar; N Cambronero; J L DeRisi; P Oishi; C C Dvorak
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

10.  Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.

Authors:  Christina Peters; Jean-Hugues Dalle; Franco Locatelli; Ulrike Poetschger; Petr Sedlacek; Jochen Buechner; Peter J Shaw; Raquel Staciuk; Marianne Ifversen; Herbert Pichler; Kim Vettenranta; Peter Svec; Olga Aleinikova; Jerry Stein; Tayfun Güngör; Jacek Toporski; Tony H Truong; Cristina Diaz-de-Heredia; Marc Bierings; Hany Ariffin; Mohammed Essa; Birgit Burkhardt; Kirk Schultz; Roland Meisel; Arjan Lankester; Marc Ansari; Martin Schrappe; Arend von Stackelberg; Adriana Balduzzi; Selim Corbacioglu; Peter Bader
Journal:  J Clin Oncol       Date:  2020-12-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.